NCT00990743 is a Phase 1 clinical trial of SYL040012 in Ocular Hypertension, sponsored by Sylentis, S.A..

Who is sponsoring NCT00990743?

NCT00990743 is sponsored by Sylentis, S.A..

What drugs are being tested in NCT00990743?

Interventions in NCT00990743: SYL040012.

What condition does NCT00990743 study?

NCT00990743 studies Ocular Hypertension, Glaucoma.

Is NCT00990743 still recruiting?

NCT00990743 is currently completed. Last updated 21 October 2010.

Last reviewed 2010-10-21 · How we verify

NCT00990743

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Study With SYL040012. Tolerance and Effect on Intraocular Pressure

Completed Phase 1 Last updated 21 October 2010

What this trial tests

Phase 1 trial testing SYL040012 in Ocular Hypertension in 30 participants. Completed in 1 June 2010.

Timeline

1 September 2009

Primary endpoint
1 June 2010

1 June 2010

Quick facts

Lead sponsor	Sylentis, S.A.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	1 September 2009
Primary completion	1 June 2010
Estimated completion	1 June 2010
Sites	1 location across Spain

Drugs / interventions tested

SYL040012 — full drug profile →

Conditions studied

Ocular Hypertension — all drugs for Ocular Hypertension →
Glaucoma — all drugs for Glaucoma →

Sponsor

Sylentis, S.A. — full company profile →

Who can join

Adults 18 to 45, any sex, with Ocular Hypertension or Glaucoma. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Part I: Local tolerance after administration of one dose of SYL040012.
Time frame: Part I: 3 days
Part II: Local tolerance after 7 days administration of SYL040012 with one dose per day.
Time frame: Part II: 11 days

Sponsor's own description

The purpose of this study is to determine whether SYL040012 is safe for the treatment of ocular hypertension and glaucoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Noncoding RNA therapeutics - challenges and potential solutions.
Winkle M, El-Daly SM, Fabbri M, Calin GA. · · 2021 · cited 1123× · PMID 34145432 · DOI 10.1038/s41573-021-00219-z
Therapeutic siRNA: state of the art.
Hu B, Zhong L, Weng Y, Peng L, et al · · 2020 · cited 991× · PMID 32561705 · DOI 10.1038/s41392-020-0207-x
RNA-based therapeutics: current progress and future prospects.
Burnett JC, Rossi JJ. · · 2012 · cited 648× · PMID 22284355 · DOI 10.1016/j.chembiol.2011.12.008
Preclinical and clinical development of siRNA-based therapeutics.
Ozcan G, Ozpolat B, Coleman RL, Sood AK, et al · · 2015 · cited 331× · PMID 25666164 · DOI 10.1016/j.addr.2015.01.007
Current progress of siRNA/shRNA therapeutics in clinical trials.
Burnett JC, Rossi JJ, Tiemann K. · · 2011 · cited 313× · PMID 21744502 · DOI 10.1002/biot.201100054
Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine.
Xue HY, Liu S, Wong HL. · · 2014 · cited 179× · PMID 24552562 · DOI 10.2217/nnm.13.204
Progress toward in vivo use of siRNAs-II.
Rettig GR, Behlke MA. · · 2012 · cited 163× · PMID 22186795 · DOI 10.1038/mt.2011.263
The landscape of nanoparticle-based siRNA delivery and therapeutic development.
Moazzam M, Zhang M, Hussain A, Yu X, et al · · 2024 · cited 116× · PMID 38204162 · DOI 10.1016/j.ymthe.2024.01.005

Verify or expand the search:

Other recruiting trials for Ocular Hypertension

Currently open trials in the same condition.

NCT07390890 — DSLT for Reducing Medication in Glaucoma · recruiting
NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
NCT06629649 — Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers · NA · recruiting
NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting

Other Sylentis, S.A. trials

Trials by the same sponsor.

NCT05637255 — A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-rel · Phase 2 · completed
NCT05310422 — Safety Study of Tivanisiran to Treat Dry Eye · Phase 3 · completed
NCT04819269 — Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome · Phase 3 · completed
NCT04782271 — Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops · Phase 1 · completed
NCT03108664 — HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED) · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00990743 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sylentis, S.A.
Last refreshed: 21 October 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00990743.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing